Jiangsu Putai Pharmaceutical Technology

Jiangsu Putai Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Taizhou, China, focused on the discovery and development of innovative small molecule drugs. The company primarily targets oncology and metabolic diseases, with a lead program, PT-001, which is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. PT-001 is designed to treat non-small cell lung cancer by specifically targeting the T790M resistance mutation. Operating out of the China Medical City (CMC) hub, Jiangsu Putai leverages its internal research and development capabilities to advance a pipeline of high-potency, low-toxicity therapeutic agents. The company aims to address significant unmet medical needs within the Chinese oncology market through precision medicine.